adenine has been researched along with vidarabine in 76 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 31 (40.79) | 18.7374 |
1990's | 3 (3.95) | 18.2507 |
2000's | 6 (7.89) | 29.6817 |
2010's | 26 (34.21) | 24.3611 |
2020's | 10 (13.16) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
de Koning, HP; Eze, AA; Gustavsson, AL; Hammarström, LG; Lundbäck, T; Olivera, GC; Rottenberg, ME; Sjöberg, B; Svensson, R; Vodnala, SK; Yeheskieli, E | 1 |
Cohen, SS; North, TW | 1 |
Brunner, WC; Maestre, MF | 1 |
Cohen, SS; Plunkett, W | 2 |
Cohen, SS; Lapi, L | 1 |
Cohen, SS | 1 |
Alexander, L; Chubb, S; Loo, TL; Plunkett, W | 2 |
Ahland, MP; Balis, ME; Brown, GF; Trotta, PP | 1 |
Bowman, K; Gangarosa, LP; Green, K; Hill, JM; Hull, DS; Park, NH; Tuggle, CL | 1 |
Rice, LS; Shannon, WM; Suling, WJ | 1 |
Belt, JA; Cass, CE; Dagnino, L; Gati, WP; Paterson, AR; Vijayalakshmi, D | 1 |
Inoue, Y; Kimura, A; Ling, F | 1 |
Chisaka, O; Matsubara, K; Nagahata, T; Tsurimoto, T; Ueda, K | 1 |
De Clercq, E; Kitaoka, S; Konno, T | 1 |
Huang, P; Plunkett, W | 1 |
Bordoni, T; Cristalli, G; Franchetti, P; Geroni, C; Grifantini, M; Lupidi, G; Riva, F; Verini, MA; Vittori, S | 1 |
Kontinen, VP; Pispa, JP | 1 |
Baraĭ, VN; ERoshevskaia, LA; Kvasiuk, EI; Mikhaĭlopulo, IA; Zinchenko, AI | 1 |
Silverstein, SC; Sung, SJ | 1 |
Hsiao, N; Lum, CT; Najarian, JS; Sutherland, DE | 1 |
Plunkett, W | 1 |
Arnett, G; Cohen, SS; North, TW; Schabel, FM; Shannon, WM | 1 |
Cohen, T; Manor, D; Margalith, M | 1 |
Decker, DM; Magnuson, JA; Magnuson, NS; Perryman, LE | 1 |
Balis, ME; Dunzendorfer, U; Fogh, J; Releyea, N; Whitmore, WF | 1 |
Avramis, VI; Plunkett, W | 1 |
Huisman, W; Nordemann, HD; Stolk, LM; Vyth, A | 1 |
Coleman, MS; Deibel, MR; Hutton, JJ | 1 |
Eloranta, TO; Kajander, EO; Raina, AM | 1 |
Chiang, PK; Guranowski, A; Segall, JE | 1 |
Helland, S; Ueland, PM | 1 |
Gangarosa, LP; Hill, JM; Park, NH; Wiggins, CA | 1 |
Mimura, Y; Naito, T; Nitta, K; Shiota, H | 1 |
Boyer, SH; Colby, TJ; Erion, MD; Gomez-Galeno, J; Lemus, RH; Matelich, MC; Reddy, KR; Schanzer, J; Ugarkar, BG; Van Poelje, PD | 1 |
Kamel, AM; Munson, B | 1 |
Bauta, WE; Cantrell, WR; Schulmeier, BE | 1 |
Cervasi, B; Engram, J; Fraternale, A; Lawson, B; Magnani, M; Menotta, M; Paiardini, M; Perno, CF; Piedimonte, G; Serafini, S; Silvestri, G; Staprans, SI | 1 |
Ctrnáctá, V; Hrdý, I; Keithly, JS; Stejskal, F | 1 |
Fijolek, A; Hofer, A; Mäser, P; Mosimann, M; Rofougaran, R; Vodnala, M | 1 |
Almasan, A; Hill, BT; Kalaycio, M; Mazumder, S; Sharma, A; Singh, K | 1 |
Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW | 1 |
Aoki, S | 1 |
Brown, JR; O'Brien, SM; Porter, DL | 1 |
Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
Byrd, JC; Gordon, A; Guinn, D; Hertlein, E; Jaglowski, S; Johnson, AJ; Larson, R; Lin, TS; Maddocks, K; Marcucci, G; Ruppert, AS; Woyach, J | 1 |
Bergmann, M; Wendtner, CM | 1 |
Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A | 1 |
Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
Treon, SP | 1 |
Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R | 1 |
Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L | 1 |
Kachler, S; Klotz, KN | 1 |
Brown, JR; Hallek, MJ; Pagel, JM | 1 |
Aurran-Schleinitz, T; Birsen, R; Bonnet, C; Boubaya, M; Choquet, S; Cymbalista, F; Delarue, R; Dietrich, PY; Dupuis, J; Fahri, J; Lamy, T; Leblond, V; Lemal, R; Lepretre, S; Levy, V; Michallet, AS; Re, D; Troussard, X; Wanquet, A; Ysebaert, L | 1 |
Baculea, S; Cote, S; Diels, J; Van Sanden, S | 1 |
Baculea, S; Côté, S; Diels, J; Dorman, E; Fahrbach, K; Sanden, SV; Xu, Y | 1 |
Jain, N | 1 |
Wierda, WG | 1 |
Wendtner, CM | 1 |
Barr, PM; Barrientos, J; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Jelinek, DF; Kay, NE; Leis, JF; Little, RF; Litzow, M; Mato, AR; Mullane, MP; O'Brien, S; Shanafelt, TD; Singh, AK; Stone, RM; Tallman, M; Wang, XV; Zhang, CC | 1 |
Stirrups, R | 1 |
Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R | 1 |
Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S | 1 |
Suzumiya, J; Takizawa, J | 1 |
Burudpakdee, C; Kabadi, SM; Near, A; Wada, K | 1 |
Allain, EP; Bat, V; Caron, P; Demirtas, D; Droit, A; Guillemette, C; Hubmann, R; Jäger, U; Joly-Beauparlant, C; Labriet, A; Le, T; Lévesque, E; Rouleau, M; Schnabl, S; Shehata, M; Staber, PB; Tremblay, S; Turcotte, V; Vaillancourt, J; Vanura, K; Villeneuve, L | 1 |
Anagnostopoulos, A; Chatzidimitriou, A; Galigalidou, C; Gemenetzi, K; Ghia, P; Ioannou, N; Iskas, M; Koravou, E; Kotouza, M; Kotta, K; Kouvatsi, A; Papazoglou, D; Pasentsis, K; Psomopoulos, F; Ramsay, AG; Scarfó, L; Stamatopoulos, K; Stavroyianni, N; Vardi, A; Vlachonikola, E | 1 |
Ahn, IE; Fleisher, T; Gaglione, E; Lotter, J; Maric, I; Mu, R; Pittaluga, S; Pleyer, C; Rampertaap, S; Rosenzweig, S; Soto, S; Stetler-Stevenson, M; Sun, C; Superata, J; Tian, X; Wiestner, A; Yuan, CM | 1 |
Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; De Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Levy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini Piocelle, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan-Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L | 1 |
Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
Ayala, A; Borthakur, G; Bose, P; Burger, J; Estrov, Z; Ferrajoli, A; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Lopez, W; O'Brien, S; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, S; Wang, W; Wang, X; Wierda, WG | 1 |
Barr, PM; Barrientos, JC; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Kay, NE; Leis, JF; Lesnick, CE; Litzow, MR; Mato, AR; Mullane, MP; O'Brien, S; Paietta, EM; Shanafelt, TD; Singh, AK; Stone, R; Tallman, MS; Tschumper, RC; Wang, XV; Zhang, CC | 1 |
9 review(s) available for adenine and vidarabine
Article | Year |
---|---|
The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA).
Topics: Adenine; Adenosine Deaminase Inhibitors; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Azepines; Cell Division; Cell Survival; Cells, Cultured; Cytarabine; Cytidine Deaminase; Cytosine Nucleotides; Deoxyribonucleosides; DNA; Humans; Inosine Nucleotides; Leukemia; Tetrahydrouridine; Vidarabine; Virus Diseases | 1977 |
[Chronic lymphocytic leukemia].
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine | 2014 |
Novel treatments for chronic lymphocytic leukemia and moving forward.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine | 2014 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine | 2016 |
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Vidarabine | 2018 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
7 trial(s) available for adenine and vidarabine
Article | Year |
---|---|
Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
Topics: Adenine; Adenosine Deaminase Inhibitors; Adult; Animals; Carcinoma, Ehrlich Tumor; Clinical Trials as Topic; Coformycin; DNA; Drug Evaluation; Drug Synergism; Humans; Leukemia P388; Leukemia, Experimental; Leukemia, Lymphoid; Male; Mice; Nucleoside Deaminases; Pentostatin; Thymidine; Vidarabine | 1985 |
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Survival Rate; Vidarabine | 2020 |
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Piperidines; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2021 |
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Rituximab; Treatment Outcome; Vidarabine | 2021 |
60 other study(ies) available for adenine and vidarabine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
Topics: Animals; Cell Survival; Cells, Cultured; Deoxyadenosines; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense; Trypanosomiasis, African | 2013 |
Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues.
Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Deoxyadenosines; DNA Replication; DNA, Viral; Drug Synergism; HeLa Cells; Nucleoside Deaminases; RNA, Viral; Simplexvirus; Vidarabine; Viral Proteins; Virus Replication | 1978 |
Circular dichroism of some mononucleosides.
Topics: Adenine; Circular Dichroism; Hydrogen-Ion Concentration; Nucleosides; Purine Nucleosides; Ribonucleosides; Spectrum Analysis; Thymidine; Uridine; Vidarabine; Water | 1975 |
Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Carcinoma, Ehrlich Tumor; Cell Survival; Drug Synergism; L Cells; Mice; Nucleoside Deaminases; Vidarabine | 1977 |
Toxicities of adenosine and 2'-deoxyadrenosine in L cells treated with inhibitors of adenosine deaminase.
Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Animals; Anti-Bacterial Agents; Azepines; Deoxyadenosines; Deoxyribonucleosides; Fibroblasts; L Cells; Mice; Nucleoside Deaminases; Vidarabine | 1977 |
Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Cells, Cultured; Coformycin; DNA, Neoplasm; Female; Leukemia, Experimental; Mice; Nucleoside Deaminases; Ribonucleosides; Time Factors; Vidarabine | 1979 |
Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Arabinonucleotides; Bone Marrow; Cell Line; Coformycin; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Intestinal Mucosa; Leukemia, Experimental; Leukemia, Lymphoid; Mice; Mice, Inbred Strains; Nucleoside Deaminases; Ribonucleosides; Time Factors; Vidarabine | 1979 |
Studies on the effects of infusion of enzyme inhibitors on mouse adenosine deaminase.
Topics: Adenine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Enzyme Inhibitors; Female; In Vitro Techniques; Isoelectric Focusing; Kinetics; Mice; Nucleoside Deaminases; Tissue Distribution; Vidarabine | 1978 |
Iontophoresis of vidarabine monophosphate into rabbit eyes.
Topics: Adenine; Adenosine; Animals; Aqueous Humor; Cornea; Eye; Hypoxanthines; Iontophoresis; Iris; Lens, Crystalline; Ophthalmic Solutions; Rabbits; Vidarabine | 1978 |
Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Azepines; Deoxyribonucleosides; Male; Mice; Mice, Inbred Strains; Nucleoside Deaminases; Time Factors; Vidarabine | 1978 |
Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
Topics: Adenine; Adenine Nucleotides; Adenosine; Adenosine Deaminase Inhibitors; Adenosine Triphosphate; Animals; Carcinoma, Ehrlich Tumor; Deamination; Deoxyadenine Nucleotides; Deoxyadenosines; Dideoxynucleotides; DNA; Drug Synergism; L Cells; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Nucleoside Deaminases; Phosphates; Purine Nucleosides; RNA; Thymidine; Uridine; Vidarabine | 1975 |
L1210/B23.1 cells express equilibrative, inhibitor-sensitive nucleoside transport activity and lack two parental nucleoside transport activities.
Topics: Adenine; Adenosine; Animals; Antiviral Agents; Biological Transport; Carrier Proteins; Cell Membrane; Clone Cells; Formycins; Kinetics; Leukemia L1210; Membrane Proteins; Mice; Mutagenesis; Nucleoside Transport Proteins; Nucleosides; Thioinosine; Thymidine; Tumor Cells, Cultured; Vidarabine | 1992 |
Purification and characterization of a novel nucleoside phosphorylase from a Klebsiella sp. and its use in the enzymatic production of adenine arabinoside.
Topics: Adenine; Chromatography, DEAE-Cellulose; Chromatography, Gel; Electrophoresis, Polyacrylamide Gel; Hydrogen-Ion Concentration; Kinetics; Klebsiella; Molecular Weight; Pentosyltransferases; Purine Nucleosides; Pyrimidine Nucleosides; Substrate Specificity; Temperature; Vidarabine | 1990 |
An in vitro system for screening anti-hepatitis B virus drugs.
Topics: Acyclovir; Adenine; Antiviral Agents; Blotting, Southern; Carcinoma, Hepatocellular; Cytarabine; Dideoxyadenosine; Dideoxynucleosides; DNA Replication; DNA, Viral; Hepatitis B virus; Humans; Interferons; Liver Neoplasms; Tumor Cells, Cultured; Vidarabine; Virus Replication; Zalcitabine; Zidovudine | 1989 |
Comparative efficacy of broad-spectrum antiviral agents as inhibitors of rotavirus replication in vitro.
Topics: Adenine; Adenosine; Amides; Antiviral Agents; Cell Line; Cytidine; Dose-Response Relationship, Drug; Pyrazoles; Ribavirin; Ribonucleosides; Ribose; Rotavirus; Tubercidin; Vidarabine; Virus Replication | 1986 |
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Binding, Competitive; Cell Line; Escherichia coli; Humans; Kidney; Kinetics; Leukemia; Liver; Mice; Phosphates; Purine Nucleosides; Rats; Vidarabine | 1987 |
Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Antineoplastic Agents; Antiviral Agents; Drug Synergism; Humans; Mice; Nucleoside Deaminases; Structure-Activity Relationship; Vidarabine | 1988 |
Enhancement of biotinidase activity in mouse serum by inhibitors of methylation.
Topics: Adenine; Adenosine; Amidohydrolases; Animals; Biotinidase; Coformycin; Ethionine; Female; Liver; Methylation; Mice; Pentostatin; Vidarabine | 1987 |
[Preparative synthesis of the antiviral nucleoside 9-beta-D-arabinofuranosyladenine by using bacterial cells].
Topics: Adenine; Antiviral Agents; Buffers; Culture Media; Cytarabine; Dose-Response Relationship, Drug; Escherichia coli; Hydrogen-Ion Concentration; Temperature; Vidarabine | 1986 |
Inhibition of macrophage phagocytosis by methylation inhibitors. Lack of correlation of protein carboxymethylation and phospholipid methylation with phagocytosis.
Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Cells, Cultured; Deoxyadenosines; Homocysteine; Kinetics; Macrophages; Methylation; Mice; Phagocytosis; Phospholipids; Proteins; Vidarabine | 1985 |
Relevance of adenosine deaminase to organ transplantation.
Topics: Adenine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Coformycin; Female; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nucleoside Deaminases; Pentostatin; Skin Transplantation; Splenectomy; T-Lymphocytes; Vidarabine | 1985 |
Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice.
Topics: Adenine; Adenosine Deaminase Inhibitors; Animals; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Female; Herpes Simplex; Mice; Nucleoside Deaminases; Simplexvirus; Vidarabine | 1980 |
Cytotoxicity of arabinofuranosyladenine and erythro-9-(2-hydroxy-3-nonyl) adenine to Epstein-Barr virus producer and nonproducer lymphoma cells in culture.
Topics: Adenine; Animals; Burkitt Lymphoma; Callitrichinae; Cell Division; Cell Line; Cell Survival; Cells, Cultured; Genes, Viral; Herpesvirus 4, Human; Humans; Infectious Mononucleosis; Neoplasms, Experimental; Vidarabine | 1983 |
Inhibition of equine S-adenohomocysteine hydrolase by 2'-deoxyadenosine.
Topics: Adenine; Adenosine; Adenosylhomocysteinase; Animals; Deoxyadenosines; Horses; Hydrolases; Liver; S-Adenosylhomocysteine; Vidarabine | 1984 |
Some effects of inhibitors of polyamine synthesis on experimental prostatic cancer.
Topics: Adenine; Adenocarcinoma; Adenosylmethionine Decarboxylase; Animals; Carboxy-Lyases; Eflornithine; Guanidines; Male; Mice; Mice, Nude; Mitoguazone; Ornithine; Ornithine Decarboxylase Inhibitors; Polyamines; Prostatic Neoplasms; Rats; Vidarabine | 1984 |
2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine.
Topics: Adenine; Adenosine Triphosphate; Animals; Arabinonucleotides; Cell Line; Chromatography, High Pressure Liquid; Leukemia P388; Leukemia, Experimental; Mice; Vidarabine | 1983 |
Formulation of a stable vidarabine infusion fluid.
Topics: Adenine; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Humans; Infusions, Parenteral; Vidarabine | 1983 |
Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
Topics: Adenine; Adenosine Deaminase Inhibitors; Cell Line; Coformycin; Deoxyadenosines; Enzyme Inhibitors; Humans; Leukemia, Lymphoid; Nucleoside Deaminases; Pentostatin; Phosphorylation; Vidarabine | 1981 |
Effect of 9-beta-D-arabinofuranosyladenine and erythro-9-(2-hydroxy-3-nonyl) adenine on the metabolism of S-adenosylhomocysteine, S-adenosylmethionine, and adenosine in rat liver.
Topics: Adenine; Adenosine; Adenosylhomocysteinase; Animals; Female; Homocysteine; Hydrolases; Liver; Rats; S-Adenosylhomocysteine; S-Adenosylmethionine; Vidarabine | 1982 |
Irreversible inhibition of S-adenosylhomocysteine hydrolase by nucleoside analogs.
Topics: 2-Chloroadenosine; Adenine; Adenosine; Adenosylhomocysteinase; Animals; Cattle; Chemical Phenomena; Chemistry; Hydrolases; Kinetics; Liver; Nucleosides; Structure-Activity Relationship; Vidarabine | 1981 |
The relation between the functions of 9-beta-D-arabinofuranosyladenine as inactivator and substrate of S-adenosylhomocysteine hydrolase.
Topics: Adenine; Adenosylhomocysteinase; Animals; Chromatography, Gel; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Hydrolases; In Vitro Techniques; Kinetics; Mice; NAD; Oxidation-Reduction; Vidarabine | 1981 |
Increased penetration of nonelectrolytes into mouse skin during iontophoretic water transport (iontohydrokinesis).
Topics: Adenine; Animals; Hypoxanthines; Iontophoresis; Male; Mice; Skin Absorption; Sodium Chloride; Thymidine; Vidarabine; Water | 1980 |
[Sensitivities to other antiviral drugs and thymidine kinase activity of aciclovir-resistant herpes simplex virus type 1].
Topics: Acyclovir; Adenine; Antiviral Agents; Drug Resistance, Microbial; Ganciclovir; Guanine; Herpesvirus 1, Human; Humans; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Thymidine Kinase; Vidarabine | 1994 |
Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver.
Topics: Adenine; Animals; Catalysis; Cytarabine; Cytochrome P-450 Enzyme System; Drug Delivery Systems; Drug Design; Hepatocytes; Humans; Liver; Male; Organophosphonates; Phosphates; Phosphotransferases; Prodrugs; Rats; Stereoisomerism; Time Factors; Vidarabine | 2004 |
Collisionally-induced dissociation of purine antiviral agents: mechanisms of ion formation using gas phase hydrogen/deuterium exchange and electrospray ionization tandem mass spectrometry.
Topics: Acyclovir; Adenine; Antiviral Agents; Deuterium Exchange Measurement; Gases; Guanine; Hydrogen; Ions; Molecular Structure; Protons; Purines; Spectrometry, Mass, Electrospray Ionization; Vidarabine; Vidarabine Phosphate | 2004 |
Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine.
Topics: Adenine; Alkylation; Arabinose; Nucleic Acid Conformation; Pentanols; Stereoisomerism; Vidarabine | 2006 |
Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.
Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cercocebus atys; Drug Carriers; Erythrocytes; Female; Humans; Macrophages; Male; Myeloablative Agonists; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; STAT1 Transcription Factor; T-Lymphocyte Subsets; Tenofovir; Vidarabine; Viremia; Virus Replication | 2006 |
Characterization of S-adenosylhomocysteine hydrolase from Cryptosporidium parvum.
Topics: Adenine; Adenosylhomocysteinase; Amino Acid Sequence; Animals; Cryptosporidium parvum; Escherichia coli; Gene Expression; Gene Expression Regulation, Developmental; Introns; Molecular Sequence Data; Molecular Weight; Recombinant Fusion Proteins; RNA, Messenger; RNA, Protozoan; Sequence Homology, Amino Acid; Vidarabine | 2007 |
Adenosine kinase mediates high affinity adenosine salvage in Trypanosoma brucei.
Topics: Adenine; Adenosine Kinase; Animals; Antimetabolites; Catalysis; Guanosine Triphosphate; Humans; Leishmania donovani; Membrane Transport Proteins; Protozoan Proteins; Recombinant Proteins; Substrate Specificity; Trypanosoma brucei brucei; Trypanosomiasis, African; Vidarabine | 2008 |
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Bcl-2-Like Protein 11; Beclin-1; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Ubiquitin-Activating Enzymes; Vidarabine | 2013 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Gene Expression Regulation, Leukemic; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Multivariate Analysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Vidarabine | 2015 |
[Chronic lymphatic leukemia].
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Rituximab; Vidarabine | 2015 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Cell Death; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Dose-Response Relationship, Drug; Enzymes; Flucytosine; Fluorouracil; Humans; Methanol; Molecular Targeted Therapy; Organoselenium Compounds; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Recombinant Fusion Proteins; Selenomethionine; Taxoids; Tubulin Modulators; Vidarabine | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclophosphamide; Cytokines; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Vidarabine | 2015 |
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2016 |
Inhibitors of membranous adenylyl cyclases with affinity for adenosine receptors.
Topics: Adenine; Adenosine Triphosphate; Adenylyl Cyclase Inhibitors; Animals; Cell Membrane; CHO Cells; Cricetulus; Humans; Receptors, Purinergic P1; Transfection; Vidarabine | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cohort Studies; Disease Management; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Neoplasm Invasiveness; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine | 2017 |
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine | 2017 |
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine | 2019 |
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2019 |
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine | 2019 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2020 |
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Female; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Retrospective Studies; Rituximab; United States; Vidarabine; Young Adult | 2020 |
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mass Spectrometry; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Piperidines; Purines; Quinazolinones; Vidarabine | 2020 |
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunological Synapses; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Rituximab; T-Lymphocytes; Vidarabine | 2020 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |